# Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

> **NCT07316686** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** Docetaxel 50mg/m2
- **DRUG:** Docetaxel 60mg/m2
- **DRUG:** Docetaxel 75 mg/m²
- **RADIATION:** 177Lu-PSMA-I&T

## Key facts

- **NCT ID:** NCT07316686
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07316686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07316686, "Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07316686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*